文献速递自身免疫性与大疱性皮肤病

利妥昔单抗对比吗替麦考酚酯治疗寻常型天疱疮的成本-效用分析

Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该成本-效用分析从澳大利亚医疗部门视角,用24个月Markov模型模拟未治疗的中重度寻常型天疱疮成人患者。与吗替麦考酚酯相比,一线利妥昔单抗生物类似药减少费用639澳元并提高0.07个QALY,ICER为-8818澳元/QALY,更具成本效益。

要点

  • 中重度寻常型天疱疮一线利妥昔单抗生物类似药较吗替麦考酚酯费用低639澳元且QALY高0.07。
  • ICER为-8818澳元/QALY,利妥昔单抗生物类似药更有效且成本更低。
  • 敏感性分析显示利妥昔单抗生物类似药在多种参数和支付意愿阈值下仍具成本效益。

核心结论

  • 在中重度寻常型天疱疮的成本-效用分析中,利妥昔单抗生物类似药较吗替麦考酚酯具成本效益。
  • 作者认为进一步研究更长时间 horizon 的成本效益是必要的,但本研究有利结果提示利妥昔单抗生物类似药的高采购成本可能被其有效性抵消,并为支持其列入药品福利计划提供经济学证据。

研究设计与样本

  • 成本-效用分析,采用24个月时间 horizon,从澳大利亚医疗部门视角开展。
  • 构建Markov队列模型,模拟未治疗的中重度寻常型天疱疮成人患者接受一线利妥昔单抗生物类似药或吗替麦考酚酯后的疾病进展。
  • 模拟队列在控制疾病、未控制疾病和死亡三种状态间转换,疗效与效用数据来自已发表文献,成本数据主要来自已发表政府数据。
  • 进行单因素和概率敏感性分析评估不确定性,主要结局为24个月内费用和QALY的变化及增量成本效果比(ICER)。

主要发现

  • 模拟的未治疗患者队列平均年龄50.8岁,女性与男性比为1.24,按Harman标准分类为中重度疾病。
  • 与吗替麦考酚酯相比,一线利妥昔单抗生物类似药费用减少639澳元,QALY提高0.07,ICER为-8818澳元/QALY。
  • 敏感性分析显示,在费用、效用和转移概率输入参数的一系列取值及支付意愿阈值下,利妥昔单抗生物类似药均保持成本效益。

关键数值与推荐

  • 利妥昔单抗生物类似药较吗替麦考酚酯费用减少639澳元(成本更低)。
  • 利妥昔单抗生物类似药较吗替麦考酚酯QALY提高0.07(更有效)。
  • ICER为-8818澳元/QALY。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步研究更长时间 horizon 的成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is an increasing body of literature that supports the use of rituximab as a first-line steroid-sparing agent in pemphigus vulgaris. However, the cost of rituximab is substantial compared with conventional agents, and there are limited health economic data to justify its use. OBJECTIVE: To evaluate the cost-effectiveness of rituximab biosimilars relative to mycophenolate mofetil as a first-line steroid-sparing agent for moderate to severe pemphigus vulgaris. DESIGN, SETTING, AND PARTICIPANTS: A cost-utility analysis over a 24-month time horizon was conducted from the perspective of the Australian health care sector using a modeled cohort of treatment-naive adult patients with moderate to severe pemphigus vulgaris. A Markov cohort model was constructed to simulate disease progression following first-line treatment with rituximab biosimilars or mycophenolate mofetil. The simulated cohort transitioned between controlled disease, uncontrolled disease, and death. Efficacy and utility data were obtained from available published literature. Cost data were primarily obtained from published government data. One-way and probabilistic sensitivity analyses were performed to assess uncertainty. Primary outcomes were the changes in cost and quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) over the 24 months. INTERVENTIONS: Rituximab biosimilars and mycophenolate mofetil. RESULTS: The simulated cohort of treatment-naive patients had a mean age of 50.8 years, a female-to-male ratio of 1.24, and moderate to severe disease as classified by the Harman criteria. First-line rituximab biosimilars were associated with a cost reduction of AU$639 and an improvement of 0.07 QALYs compared with mycophenolate mofetil, resulting in an ICER of -AU$8818/QALY. Rituximab biosimilars were therefore more effective and less costly compared with mycophenolate mofetil. Sensitivity analyses demonstrated that rituximab biosimilars remained cost-effective across a range of values for cost, utility, and transition probability input parameters and willingness-to-pay thresholds. CONCLUSIONS AND RELEVANCE: In this cost-utility analysis, rituximab biosimilars were cost-effective compared with mycophenolate mofetil for moderate to severe pemphigus vulgaris. Further investigation into its cost-effectiveness over a longer time horizon is necessary, but the favorable results of this study suggest that the high acquisition costs of rituximab biosimilars may be offset by its effectiveness and provide economic evidence in support of its listing on the Pharmaceutical Benefits Scheme for pemphigus vulgaris.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen MKY, Vissapragada R, Bulamu N, et al. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris. JAMA Dermatol. 2022. PMID: 35895045. doi:10.1001/jamadermatol.2022.2878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。